DSG3/1 CAART
Alternative Names: DSG3/1-CAARTLatest Information Update: 28 Nov 2023
At a glance
- Originator University of Pennsylvania
- Developer Cabaletta Bio
- Class Gene therapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Pemphigus vulgaris
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for preclinical development in Pemphigus-vulgaris in USA (Parenteral)
- 07 Oct 2019 Preclinical trials in Pemphigus vulgaris in USA (Parenteral) prior to October 2019
- 30 Sep 2019 Cabaletta Bio has four pending USA patent applications and counterpart patent applications pending in Canada, China and Europe, which if issued, would be expected to expire in 2035